CONFERENCE UPDATE: ASH 2021

Pivotal results of phase 1/2 study: Novel mosunetuzumab elicits clinically durable response and deep remission in rrFL patients who underwent ≥2 prior lines of therapy

28 Jan 2022

Get access to our exclusive articles.